Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
McKesson
Medtronic

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

DIFFERIN Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Differin, and what generic alternatives are available?

Differin is a drug marketed by Galderma Labs Lp and is included in five NDAs. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-five patent family members in twenty-two countries.

The generic ingredient in DIFFERIN is adapalene. There are twelve drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the adapalene profile page.

Summary for DIFFERIN
International Patents:55
US Patents:9
Applicants:1
NDAs:5
Suppliers / Packagers: 5
Bulk Api Vendors: 108
Clinical Trials: 19
Patent Applications: 2,363
Formulation / Manufacturing:see details
Drug Prices: Drug price information for DIFFERIN
Drug Sales Revenues: Drug sales revenues for DIFFERIN
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for DIFFERIN
DailyMed Link:DIFFERIN at DailyMed
Drug patent expirations by year for DIFFERIN
Drug Prices for DIFFERIN

See drug prices for DIFFERIN

Drug Sales Revenue Trends for DIFFERIN

See drug sales revenues for DIFFERIN

Recent Clinical Trials for DIFFERIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Catawba Research, LLCPhase 3
Aleor Dermaceuticals LimitedPhase 3
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical LimitedPhase 3

See all DIFFERIN clinical trials

Recent Litigation for DIFFERIN

Identify potential future generic entrants

District Court Litigation
Case NameDate
Galderma Laboratories LP v. Actavis Mid Atlantic LLC2010-10-15
Galderma Laboratories LP v. Tolmar Inc.

See all DIFFERIN litigation

Pharmacology for DIFFERIN
Drug ClassRetinoid
Synonyms for DIFFERIN
106685-40-9
1L4806J2QF
2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo(3.3.1.1(sup 3,7))dec-1-ylphenyl)-
2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-
4CA-0111
6-(3-((3r,5r,7r)-adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid
6-(4-Methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid
6-[3-(1-adamantyl)-4-methoxy-phenyl]naphthalene-2-carboxylic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalene-carboxylic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalenecarboxylic acid
6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthoic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid
6-[3-(adamantan-1-yl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
6-[4-methoxy-3-(tricyclo[3.3.1.1~3,7~]dec-1-yl)phenyl]naphthalene-2-carboxylic acid
6-[4-methoxy-3-(tricyclo[3.3.1.13,7]dec-1-yl)phenyl]naphthalene-2-carboxylic acid
685A409
A2549
A801483
AB0013899
AB01274764_03
AB01274764_04
AB01274764-01
AB01274764-02
AB13763
AB2000023
ABP000590
AC-1974
AC1L1SOH
AC1Q5USH
Adaferin
Adapalen
ADAPALENE
Adapalene (JAN/USAN/INN)
Adapalene [USAN:BAN:INN]
Adapalene [USAN:INN:BAN]
Adapalene for peak identification, European Pharmacopoeia (EP) Reference Standard
Adapalene, >=98% (HPLC)
Adapalene, European Pharmacopoeia (EP) Reference Standard
Adapalene, Pharmaceutical Secondary Standard; Certified Reference Material
Adapalene, United States Pharmacopeia (USP) Reference Standard
Adapalene/
Adapaleno
Adapaleno [INN-Spanish]
Adapalenum
Adapalenum [INN-Latin]
AJ-45604
AK-72900
AKOS005145841
AKOS015895391
AN-593
AOB6389
API0001385
BC205779
BCP02081
BCP9000231
BDBM50048280
BIDD:GT0264
BR-72900
BRD-K33127281-001-01-5
C28H28O3
CAS-106685-40-9
CCG-213060
CCG-221237
CD 271
CD-271
CD271
CHEBI:31174
CHEMBL1265
CHEMBL76401
CPD000466349
CS-1789
CTK8E8906
D01112
DB00210
Differin (TN)
Differin Gel
Differin Gel 0.1%
Differin, Teva, Pimpal, Gallet, Adelene, Adeferin
Differine
DSSTox_CID_26481
DSSTox_GSID_46481
DSSTox_RID_81652
DTXSID5046481
EBD19549
F2173-0588
FT-0631040
GTPL5429
HMS3264F15
HMS3654F11
HMS3715H16
HY-B0091
I06-0642
I810
KB-246947
KS-000002B5
KS-1196
LS-172017
LZCDAPDGXCYOEH-UHFFFAOYSA-N
MFCD03106112
MLS000759463
MLS006010036
MolPort-003-986-211
NAP030
NCGC00164617-01
NCGC00164617-02
NCGC00164617-04
NCGC00164617-05
RTR-001330
S-3513
s1276
SAM001246663
SC-17327
SCHEMBL2747
SMR000466349
SMR002529673
SR-01000942194
SR-01000942194-2
ST2412159
STL453114
SW219282-1
TL8000241
Tox21_112236
Tox21_112236_1
TR-001330
UNII-1L4806J2QF
ZINC3784182

US Patents and Regulatory Information for DIFFERIN

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galderma Labs Lp DIFFERIN adapalene CREAM;TOPICAL 020748-001 May 26, 2000 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Galderma Labs Lp DIFFERIN adapalene SOLUTION;TOPICAL 020338-001 May 31, 1996 DISCN Yes No   Start Trial   Start Trial   Start Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 020380-002 Jul 8, 2016 OTC Yes Yes   Start Trial   Start Trial   Start Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Expired US Patents for DIFFERIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Galderma Labs Lp DIFFERIN adapalene CREAM;TOPICAL 020748-001 May 26, 2000   Start Trial   Start Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007   Start Trial   Start Trial
Galderma Labs Lp DIFFERIN adapalene SOLUTION;TOPICAL 020338-001 May 31, 1996   Start Trial   Start Trial
Galderma Labs Lp DIFFERIN adapalene SOLUTION;TOPICAL 020338-001 May 31, 1996   Start Trial   Start Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007   Start Trial   Start Trial
Galderma Labs Lp DIFFERIN adapalene CREAM;TOPICAL 020748-001 May 26, 2000   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or Start Trial

Supplementary Protection Certificates for DIFFERIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1458369 SPC/GB10/005 United Kingdom   Start Trial PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1458369 08C0024 France   Start Trial PRODUCT NAME: ADAPALENE - PEROXYDE DE BENZOLE; REGISTRATION NO/DATE IN FRANCE: NL 33724 DU 20080123; REGISTRATION NO/DATE AT EEC: 40440 DU 20071218
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Medtronic
McKinsey
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
 NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

DrugPatentWatch reviews